Perfluorohexyl Octane Eye Drops (Miebo) is a new type of semifluorinated alkane eye drops. Approved in the United States in 2023, it is specifically used to treat the signs and symptoms of dry eye disease.

Precautions for Using Perfluorohexyl Octane Eye Drops (Miebo)

Contraindications

Patients with a history of allergy to perfluorohexyl octane are prohibited from using this product.

If hypersensitivity reactions such as eyelid swelling, itching, or difficulty breathing occur after medication, the drug must be discontinued immediately and medical attention sought.

Specifications for Contact Lens Use

Contact lenses must be removed before using the medication, and you should wait for at least 30 minutes after medication before reinserting them.

The active ingredients of the drug may be adsorbed by the contact lenses; direct contact between the drug and lenses may cause blurred vision or irritative symptoms.

Medication Warnings for Special Populations

Pregnant Women: Sufficient research on the use of this drug during human pregnancy is lacking. Animal experiments have shown that when rabbits were given doses ≥41 times the recommended human ophthalmic dose, miscarriages and decreased fetal weight occurred. The drug should be used only after carefully weighing the benefits and risks.

Lactating Women: There is no data indicating whether the drug enters breast milk. It is recommended to use the drug only when clinically necessary and to monitor the infant's reactions.

Children: The efficacy of this drug in populations under 18 years of age has not been established.

Medication Monitoring for Perfluorohexyl Octane Eye Drops (Miebo)

Adverse Reaction Monitoring

Common Reactions: Blurred vision (incidence rate of approximately 1-3%) and conjunctival hyperemia.

Countermeasures: Mild blurred vision usually resolves on its own within a few minutes after instillation.

If symptoms persist or worsen, a follow-up visit to the doctor is required promptly.

In case of allergic reactions, the drug must be discontinued immediately and the doctor informed.

Long-Term Use Management

After opening the bottle, the drug can be used continuously within the expiration date marked on the packaging.

Storage Conditions: Store at room temperature between 15℃ and 25℃.

Check the physical properties of the liquid regularly; if turbidity or discoloration occurs, discontinue use immediately.

Patient Education and Self-Management

Medication Adherence: Use the drug strictly at a frequency of 4 times a day, 1 drop each time; do not increase or decrease the dosage arbitrarily.

Importance of Regular Follow-Up: Attend regular follow-up visits as required by the doctor to evaluate the treatment effect and adjust the treatment plan in a timely manner.

Emergency Handling: If severe eye pain, persistent blurred vision, or abnormal eye discharge occurs, discontinue the drug immediately and seek medical attention promptly.